EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Safety and Efficacy of Fecal Microbiota Transplantation in Alleviating Symptoms of Parkinson's Disease: A Randomized, Placebo‐Controlled, Double‐Blinded Study

Monika Figura, Łukasz Milanowski, Julia Maya Nowak, Aleksandra Antoniak, Mateusz Kopczyński, Weronika Zając, Karol Sadowski, Łukasz Hołubiuk, Weronika Walęcik-Kot, Stanisław Szlufik, Andrzej Friedman, Barbara Kaczmarczyk und 2 weitere

Annals of Neurology · 2026-07 · 100 (1) · 10-21

DOI: 10.1002/ana.78153 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Neurology, online erschienen am 12.02.2026. Verfasst von Monika Figura und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, Poland. Hauptthemen laut MEDLINE: Fecal Microbiota Transplantation, Parkinson Disease. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Biocodex Microbiota Foundation National Grant, Medical University of Warsaw, Warszawski Uniwersytet Medyczny.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Changes in the gut microbiome may be involved in the pathogenesis and progression of Parkinson's disease ( PD ). This randomized, placebo‐controlled, double‐blinded study aimed to assess the effects of fecal microbiota transplantation ( FMT ) on the manifestation of the motor symptoms of PD (The Movement Disorders Society ‐ Unified Parkinson's Disease Rating Scale Part III [MDS‐UPDRS III]) over a 12 month long observation and non‐motor symptoms as secondary objectives: the Movement Disorders Society‐Non‐Motor Rating Scale; EuroQol ‐5 Dimension; PD Quality‐of‐Life Questionnaire; Montreal Cognitive Assessment ( MoCA ); UPDRS I, II , and IV ; Gastrointestinal Dysfunction Scale for PD ; modified Constipation Assessment Scale; and levodopa equivalent dose.

Methods

The patients were randomly assigned to receive either fecal microbiota (Mbiotix, Human Biome Institute) or placebo (auto‐fecal microbiota, prepared from the patient's stool) in a 1:1 ratio. The fecal microbiota transplantation was performed via colonoscopy. Assessments were performed before and after 12 months for the MoCA and at 1, 3, 6, and 12 months for the other scales. Intention‐to‐treat analysis was performed using a multivariable mixed regression model.

Results

Of the 59 patients included, 28 were randomly assigned to the Mbiotix group (median age = 65 years; 15 male patients) and 31 to the placebo group (median age = 63 years; 14 male patients). No significant differences were observed in the MDS‐UPDRS III “OFF” state score at 12 months between groups (1.50 points, 95% confidence interval [CI] = −4.28 to 7.28, p = 1.00), however, some non‐motor symptoms improved in different study timepoints.

Interpretation

A single FMT does not influence motor symptoms manifestation in patients with PD but could improve non‐motor functioning via gut‐brain axis. Trial registration information: Clinical Trial ID NCT05204641 was submitted on November 29, 2021. The first patient was enrolled on January 4, 2022. ANN NEUROL 2026;100:10–21

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fecal Microbiota TransplantationParkinson DiseaseHumansMaleDouble-Blind MethodFemaleMiddle AgedAgedTreatment OutcomeQuality of Life

Autor:innen und Institutionen

  • Department of Neurology, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, Poland.
  • Medical University of Warsaw, Warsaw, Poland.
  • Department of Gastroenterology, Masovian Brodnowski Hospital, Warsaw, Poland.
  • Human Biome Institute, Gdansk, Warsaw, Poland.
  • Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.

Förderung

  • Biocodex Microbiota Foundation National Grant
  • Medical University of Warsaw
  • Warszawski Uniwersytet Medyczny

Zitieren

APA

Figura, M., Milanowski, Ł., Nowak, J. M., Antoniak, A., Kopczyński, M., Zając, W., Sadowski, K., Hołubiuk, Ł., Walęcik-Kot, W., Szlufik, S., Friedman, A., Kaczmarczyk, B., Biliński, J., & Koziorowski, D. (2026). Safety and Efficacy of Fecal Microbiota Transplantation in Alleviating Symptoms of Parkinson's Disease: A Randomized, Placebo‐Controlled, Double‐Blinded Study. Annals of Neurology, 100(1), 10-21. https://doi.org/10.1002/ana.78153

Vancouver

Figura M, Milanowski Ł, Nowak JM, Antoniak A, Kopczyński M, Zając W, et al. Safety and Efficacy of Fecal Microbiota Transplantation in Alleviating Symptoms of Parkinson's Disease: A Randomized, Placebo‐Controlled, Double‐Blinded Study. Annals of Neurology. 2026;100(1):10-21. doi:10.1002/ana.78153

BibTeX
@article{Figura2026,
  author = {Figura, Monika and Milanowski, Łukasz and Nowak, Julia Maya and Antoniak, Aleksandra and Kopczyński, Mateusz and Zając, Weronika and Sadowski, Karol and Hołubiuk, Łukasz and Walęcik-Kot, Weronika and Szlufik, Stanisław and Friedman, Andrzej and Kaczmarczyk, Barbara and Biliński, Jarosław and Koziorowski, Dariusz},
  title = {Safety and Efficacy of Fecal Microbiota Transplantation in Alleviating Symptoms of Parkinson's Disease: A Randomized, Placebo‐Controlled, Double‐Blinded Study},
  journal = {Annals of Neurology},
  year = {2026},
  volume = {100},
  number = {1},
  pages = {10--21},
  doi = {10.1002/ana.78153}
}
Kostenlos starten →